Eila C Skinner, MD
Urology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Skinner’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G53822 · Current
Licensed to practise in California · since 1984 · expires 2027-12-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$88,920
Medicare paid this office $88,920 for 269 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Diagnostic exam of bladder and urethra using an endoscope | 119 | $11,233 | $61 |
| Short return visit (20+ min) | 58 | $5,431 | $80 |
| Return visit (30+ min) | 34 | $4,616 | $121 |
| New patient visit (60+ min) | 21 | $3,805 | $181 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,301 | $254 |
See all 9 services
| Diagnostic exam of bladder and urethra using an endoscope | 119 | $11,233 | $61 |
| Short return visit (20+ min) | 58 | $5,431 | $80 |
| Return visit (30+ min) | 34 | $4,616 | $121 |
| New patient visit (60+ min) | 21 | $3,805 | $181 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,301 | $254 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 15 | $3,273 | $205 |
| Return visit (30+ min) | 25 | $2,194 | $88 |
| New patient visit (45+ min) | 13 | $2,065 | $159 |
| Short return visit (20+ min) | 29 | $1,960 | $58 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
269 Original Medicare patients in 2024. Average age 77 · Women 39% · Also on Medicaid 8% · Health risk score 1.72. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 74% · Chronic kidney disease 42% · Cancer 41% · Coronary heart disease 30% · Diabetes 28% · Atrial fibrillation 24% · Heart failure 17% · Depression 15% · COPD 12% · Stroke 6% · Dementia 5%.
The office billed $994,737, Medicare allowed $115,829 and paid $88,920; for 509 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 269 | 509 | 77 | 1.72 | $994,737 | $88,920 |
| 2023 | 314 | 653 | 76 | 1.55 | $1,287,391 | $108,829 |
| 2022 | 317 | 655 | 76 | 1.62 | $1,413,805 | $115,076 |
| 2021 | 272 | 556 | 76 | 1.67 | $1,366,889 | $112,679 |
| 2020 | 275 | 569 | 75 | 1.76 | $1,463,862 | $118,970 |
| 2019 | 324 | 623 | 75 | 1.95 | $1,204,023 | $129,689 |
| 2018 | 329 | 644 | 76 | 1.73 | $1,316,615 | $135,404 |
| 2017 | 352 | 658 | 75 | 1.66 | $1,198,383 | $136,068 |
| 2016 | 334 | 695 | 75 | 1.75 | $1,525,336 | $177,786 |
| 2015 | 288 | 619 | 73 | 1.65 | $1,179,823 | $144,351 |
| 2014 | 241 | 521 | 74 | 1.65 | $1,115,047 | $134,060 |
| 2013 | 202 | 455 | 73 | 1.73 | $1,016,572 | $121,753 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 13 | $25,622 | $1,971 |
| Diagnostic exam of bladder and urethra using an endoscope | 125 | $12,021 | $63 |
| Short return visit (20+ min) | 105 | $7,371 | $58 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 24 | $6,476 | $249 |
| Return visit (30+ min) | 53 | $5,771 | $82 |
| Destruction and/or removal of large growth of bladder using an endoscope | 11 | $4,423 | $340 |
| New patient visit (60+ min) | 26 | $4,008 | $154 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 16 | $3,451 | $203 |
| New patient visit (45+ min) | 27 | $2,878 | $107 |
| Long return visit (40+ min) | 21 | $2,660 | $127 |
| New patient visit (30+ min) | 19 | $1,209 | $64 |
2022: 11 services
| Diagnostic exam of bladder and urethra using an endoscope | 130 | $12,052 | $62 |
| Return visit (30+ min) | 89 | $9,171 | $82 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 30 | $6,506 | $191 |
| New patient visit (45+ min) | 39 | $4,581 | $117 |
| Destruction and/or removal of large growth of bladder using an endoscope | 13 | $4,398 | $338 |
| Short return visit (20+ min) | 62 | $4,292 | $56 |
| New patient visit (60+ min) | 23 | $3,708 | $161 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $3,376 | $241 |
| Long return visit (40+ min) | 23 | $3,205 | $134 |
| New patient visit (30+ min) | 23 | $1,678 | $73 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $1,507 | $137 |
2021: 9 services
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $12,025 | $66 |
| Return visit (30+ min) | 74 | $7,540 | $88 |
| New patient visit (60+ min) | 34 | $5,483 | $161 |
| New patient visit (45+ min) | 33 | $4,004 | $121 |
| Long return visit (40+ min) | 24 | $3,668 | $136 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 18 | $3,393 | $188 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,290 | $253 |
| Short return visit (20+ min) | 20 | $1,230 | $56 |
| Imaging of urinary tract following injection of a contrast agent | 13 | $303 | $23 |
2020: 11 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 11 | $22,494 | $2,045 |
| Diagnostic exam of bladder and urethra using an endoscope | 105 | $10,903 | $63 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $3,911 | $244 |
| Return visit (30+ min) | 48 | $3,421 | $63 |
| New patient visit (45+ min) | 27 | $2,753 | $102 |
| Short return visit (20+ min) | 51 | $2,435 | $43 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 12 | $2,272 | $189 |
| New patient visit (60+ min) | 11 | $1,719 | $156 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $1,415 | $129 |
| Long return visit (40+ min) | 11 | $1,146 | $104 |
| New patient visit (30+ min) | 15 | $1,053 | $70 |
2019: 12 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 14 | $27,847 | $1,989 |
| Diagnostic exam of bladder and urethra using an endoscope | 115 | $11,524 | $65 |
| Return visit (30+ min) | 82 | $6,627 | $68 |
| Removal of prostate | 11 | $5,964 | $542 |
| Destruction and/or removal of large growth of bladder using an endoscope | 13 | $5,030 | $359 |
| New patient visit (45+ min) | 44 | $4,928 | $112 |
| New patient visit (60+ min) | 30 | $4,244 | $141 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $4,106 | $242 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 13 | $3,056 | $218 |
| Short return visit (20+ min) | 55 | $2,639 | $43 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 13 | $2,405 | $185 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 16 | $2,369 | $139 |
2018: 12 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 14 | $27,779 | $1,984 |
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small and/or large bowel with creation of urinary opening | 11 | $21,772 | $1,979 |
| Diagnostic exam of bladder and urethra using an endoscope | 120 | $13,021 | $65 |
| Removal of prostate | 16 | $8,567 | $535 |
| New patient visit (60+ min) | 48 | $6,794 | $142 |
| Return visit (30+ min) | 86 | $6,780 | $66 |
| Destruction and/or removal of large growth of bladder using an endoscope | 13 | $4,617 | $330 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 16 | $4,590 | $255 |
| New patient visit (45+ min) | 39 | $4,225 | $108 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 18 | $3,584 | $199 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 13 | $2,562 | $183 |
| Short return visit (20+ min) | 48 | $2,166 | $41 |
2017: 11 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 16 | $31,580 | $1,974 |
| Diagnostic exam of bladder and urethra using an endoscope | 112 | $14,119 | $83 |
| New patient visit (45+ min) | 58 | $6,429 | $111 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 25 | $6,262 | $250 |
| Return visit (30+ min) | 81 | $6,061 | $63 |
| New patient visit (60+ min) | 38 | $5,569 | $147 |
| Destruction and/or removal of large growth of bladder using an endoscope | 12 | $4,240 | $353 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 17 | $3,884 | $216 |
| Short return visit (20+ min) | 51 | $2,250 | $42 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 12 | $1,994 | $153 |
| Insertion of stent in ureter using an endoscope | 12 | $892 | $74 |
2016: 11 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 21 | $41,058 | $1,955 |
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small and/or large bowel with creation of urinary opening | 12 | $25,275 | $2,106 |
| Diagnostic exam of bladder and urethra using an endoscope | 90 | $13,736 | $98 |
| New patient visit (60+ min) | 68 | $9,758 | $144 |
| Return visit (30+ min) | 97 | $7,443 | $62 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 25 | $6,995 | $250 |
| Destruction and/or removal of large growth of bladder using an endoscope | 18 | $6,665 | $351 |
| New patient visit (45+ min) | 61 | $6,646 | $109 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 16 | $2,762 | $162 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 13 | $2,757 | $212 |
| Short return visit (20+ min) | 31 | $1,230 | $40 |
2015: 10 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 18 | $35,058 | $1,948 |
| Diagnostic exam of bladder and urethra using an endoscope | 76 | $12,026 | $100 |
| Return visit (30+ min) | 91 | $7,798 | $64 |
| New patient visit (60+ min) | 42 | $6,220 | $148 |
| Destruction and/or removal of large growth of bladder using an endoscope | 16 | $5,967 | $351 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 24 | $5,954 | $248 |
| New patient visit (45+ min) | 50 | $5,544 | $111 |
| Short return visit (20+ min) | 47 | $2,228 | $38 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $1,771 | $136 |
| Long return visit (40+ min) | 13 | $1,291 | $99 |
2014: 8 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 20 | $38,148 | $1,907 |
| Diagnostic exam of bladder and urethra using an endoscope | 54 | $8,475 | $99 |
| New patient visit (60+ min) | 57 | $7,725 | $136 |
| Return visit (30+ min) | 71 | $6,155 | $62 |
| New patient visit (45+ min) | 41 | $4,465 | $109 |
| Destruction and/or removal of large growth of bladder using an endoscope | 11 | $3,927 | $327 |
| Short return visit (20+ min) | 46 | $2,586 | $40 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $1,859 | $133 |
2013: 10 services
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small and/or large bowel with creation of urinary opening | 15 | $30,586 | $2,039 |
| Removal of bladder and lymph nodes on both sides of pelvis with transplantation of ureters to small or large bowel with creation of urinary opening | 11 | $21,305 | $1,937 |
| Removal of prostate | 14 | $8,106 | $579 |
| New patient visit (60+ min) | 48 | $6,964 | $145 |
| Diagnostic exam of bladder and urethra using an endoscope | 35 | $6,005 | $105 |
| Short return visit (20+ min) | 60 | $3,687 | $42 |
| New patient visit (45+ min) | 35 | $3,543 | $101 |
| Return visit (30+ min) | 47 | $3,532 | $61 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,611 | $237 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $1,525 | $127 |
Medicaid work
$537 in 2024
Medicaid paid $537 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 12 | $537 |
| 2024 | 12 | 1 | 12 | $537 |
Drugs they prescribed that Part D paid
$7,763
Pharmacies billed $7,763 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
113 generic and 11 brand-name prescriptions · $7,763 in drug cost · 81 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gentamicin Sulfate | 53 | $1,596 | $30 |
Year by year
| 2024 | 124 | 34 | None | 9% | $7,763 |
| 2023 | 96 | 28 | 0% (0) | None | $3,525 |
| 2022 | 120 | 37 | None | None | $7,152 |
| 2021 | 95 | 27 | 0% (0) | None | $6,815 |
| 2020 | 129 | 37 | None | None | $6,852 |
| 2019 | 144 | 45 | None | 10% | $8,153 |
| 2018 | 165 | 63 | None | 15% | $10,367 |
| 2017 | 204 | 84 | None | None | $8,398 |
| 2016 | 152 | 66 | None | 13% | $8,443 |
| 2015 | 221 | 77 | None | None | $25,187 |
| 2014 | 225 | 69 | 11% (24) | None | $12,484 |
| 2013 | 169 | 56 | 12% (21) | None | $6,245 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Gentamicin Sulfate | 52 | $1,363 | $26 |
2022: 1 drug
| Gentamicin Sulfate | 53 | $987 | $19 |
2021: 1 drug
| Gentamicin Sulfate | 53 | $1,108 | $21 |
2020: 1 drug
| Gentamicin Sulfate | 54 | $1,384 | $26 |
2019: 3 drugs
| Tamsulosin | 15 | $438 | $29 |
| Gentamicin Sulfate | 21 | $426 | $20 |
| Sulfamethoxazole-Trimethoprim | 15 | $52 | $3 |
2018: 4 drugs
| Oxybutynin Chloride Er | 28 | $892 | $32 |
| Tamsulosin | 21 | $312 | $15 |
| Finasteride | 12 | $90 | $8 |
| Ciprofloxacin | 16 | $89 | $6 |
2017: 6 drugs
| Oxybutynin Chloride Er | 26 | $1,042 | $40 |
| Tamsulosin | 43 | $690 | $16 |
| Nitrofurantoin | 14 | $531 | $38 |
| Amoxicillin-Clavulanate Potass | 12 | $101 | $8 |
| Finasteride | 11 | $75 | $7 |
| Ciprofloxacin | 13 | $42 | $3 |
2016: 3 drugs
| Oxybutynin Chloride Er | 21 | $827 | $39 |
| Tamsulosin | 26 | $692 | $27 |
| Ciprofloxacin | 18 | $83 | $5 |
2015: 6 drugs
| Enoxaparin | 22 | $10,035 | $456 |
| Jalyn | 11 | $1,798 | $163 |
| Tamsulosin | 38 | $1,072 | $28 |
| Oxybutynin Chloride Er | 17 | $433 | $25 |
| Finasteride | 15 | $318 | $21 |
| Ciprofloxacin | 15 | $70 | $5 |
2014: 7 drugs
| Enoxaparin | 11 | $5,951 | $541 |
| Tamsulosin | 49 | $894 | $18 |
| Finasteride | 15 | $343 | $23 |
| Hydrocodone-Acetaminophen | 21 | $343 | $16 |
| Alfuzosin Hcl Er | 16 | $217 | $14 |
| Ciprofloxacin | 19 | $113 | $6 |
| Sodium Chloride | 11 | $17 | $2 |
2013: 5 drugs
| Tamsulosin | 34 | $613 | $18 |
| Finasteride | 26 | $612 | $24 |
| Nitrofurantoin | 15 | $603 | $40 |
| Hydrocodone-Acetaminophen | 21 | $147 | $7 |
| Ciprofloxacin | 11 | $63 | $6 |
Money from drug and device companies
$18 in 2025
| 2025 | 1 | 1 | None | $18 |
| 2024 | 1 | 1 | None | $117 |
| 2022 | 1 | 2 | None | $242 |
| 2021 | 1 | 1 | None | $79 |
| 2020 | 1 | 1 | None | $57 |
| 2019 | 2 | 2 | None | $1,229 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ambu | None | $18 | 1 payment
|
See the published payment
| Ambu | Meals · 2025-01-27 | None | $18 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $117
| Immunitybio | Anktiva | $117 | 1 payment
|
2022: $242
| UroGen Pharma | Jelmyto | $242 | 2 payments
|
2021: $79
| Astellas Pharma US | Xtandi | $79 | 1 payment
|
2020: $57
| Genentech | None | $57 | 1 payment
|
2019: $1,229
| Olympus Corporation of the Americas | Olympus Cysto-Resection | $1,080 | 1 payment
|
| Genentech USA | Tecentriq | $149 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · A Phase Ibii Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With Or Without Bacille Calmette-Guerin in Patients With High-Risk Non Muscle-Invasive Bladder Cancer · 2019 | Their institution | $99,926 |
| F. Hoffmann-La Roche AG · Atezolizumab Bcg in Nmibc High Risk Patients · 2021 | Their institution | $52,634 |
| F. Hoffmann-La Roche AG · A Phase Ibii, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With Or Without Bacille Calmette-Guerin in Patients With High-Risk Non Muscle-Invasive Bladder Cancer · 2019 | Their institution | $26,510 |
| F. Hoffmann-La Roche AG · Atezolizumab Bcg in Nmibc High Risk Patients · 2022 | Their institution | $25,830 |
| F. Hoffmann-La Roche AG · Atezolizumab Bcg in Nmibc High Risk Patients · 2020 | Their institution | $24,686 |
| F. Hoffmann-La Roche AG · A Phase Ibii Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With Or Without Bacille Calmette-Guerin in Patients With High-Risk Nonmuscle-Invasive Bladder Cancer · 2019 | Their institution | $12,648 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588673941
- Licence
- CA G53822California G53822: Current · expires 2027-12-31
- Trained
- University of Southern California Keck School of Medicine, 1983
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-05
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.